Citi analyst Wangbin Zhou reiterated a Buy rating and HK$60.00 price target on Keymed Biosciences Inc (2162:HK).The analyst comments: "Keymed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE